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DObjectives: The long-term (>20 years) results for CarboMedics mechanical valves (Sorin Group, Milano, Italy)
used for both primary surgery and reoperation have never been reported or compared.
Methods: Since 1990, a total of 787 CarboMedics valves have been implanted in 694 patients for aortic valve
replacement, including 19 redo cases in 220 patients; for mitral valve replacement, including 108 redo cases in
381 patents; and for double (aortic and mitral) valve replacement, including 29 redo cases in 93 patients. The
follow-up data were complete for 7201 patient-years in 99.3% of the patients.
Results: The hospital mortality rate of the aortic, mitral, and double valve replacement groups was 0.9%, 3.7%,
and 4.3%, respectively. The corresponding freedom from valve-related morbidity rates in each group were
66.0%, 40.6%, and 48.0% at 20 years (P ¼ .0206). A higher incidence of paravalvular leakage was observed
in the mitral and double valve replacement groups than in the aortic valve replacement group (P¼ .0019). Of the
cases of mitral paravalvular leakage after single mitral valve replacement, 97% occurred after redo single mitral
valve replacement; 73% of the cases of mitral paravalvular leakage after double valve replacement occurred
after redo double valve replacement.
Conclusions: CarboMedics mechanical valves used for both primary surgery and reoperation for aortic, mitral,
and double valve replacement can achieve satisfactory early and long-term results, even 20 years after surgery.
Care should be taken, however, to prevent paravalvular leakage in the mitral position during reoperation.
(J Thorac Cardiovasc Surg 2014;147:1493-8)The use of bioprostheses has been increasing with the im-
provements in durability1,2; however, mechanical valves
are still useful prostheses, especially for younger patients,
owing to the excellent long-term durability and freedom
from reoperation. We have used CarboMedics (CM) bileaf-
let mechanical heart valves (Sorin Group, Milano, Italy),
made of pyrolitic carbon, since 1990 and previously
reported preferable 10-year results for this prosthesis.3
With this experience, we have noted the advantages and
problems with the CM prostheses, especially in redo cases,
after preceding valve replacement.
Using the European system for cardiac operative risk
evaluation and Society of Thoracic Surgeons scores, redo
heart surgery itself has been considered a risk factor, and
the number of reoperations after valve surgery, especially
when implanted with bioprostheses, has been observed
to increase during long-term follow-up. In contrast,e Department of Cardiovascular Surgery, Kyushu University Graduate School
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The Journal of Thoracic and Carmechanical prostheses implanted in relatively younger
patients have been expected to be reliable and durable with-
out the need for additional surgery during the long-term
(>20 years after surgery). However, the long-term results
of the CM prosthesis, used for both primary and redo oper-
ations, have not yet been reported or compared. In particular,
the rates of thromboembolic and hemorrhagic complications
associated with CM valves have not been well described in
existing studies. We have analyzed our 22-year clinical ex-
perience with the CM valve for both primary and redo oper-
ations to evaluate the reliance of this second-generation
bileaflet valve.METHODS
A total of 760 patients underwent valve replacement with a CM prosthe-
sis from May 1990 to August 2012. Of these patients, 16, who had
undergone tricuspid valve replacement, were excluded for simplicity of
the analysis, and 50, who had undergone double valve replacement
(DVR; aortic valve replacement [AVR] plus mitral valve replacement
[MVR]), were excluded because they had undergone AVR with other pros-
theses. Therefore, a total of 787 CM prostheses had been implanted in 694
patients (AVR in 220 patients, MVR in 381 patients, and DVR in 93
patients) and were included in the present study. The mean patient age
was 54.9  0.94 years in the AVR group, 60.0  0.56 years in the MVR
group (P<.05 vs other groups), and 56.2  1.1 years in the DVR group.
The predominant cause of valve disease was rheumatic or degenerative
heart disease in all groups (Table 1). Various aorta-related diseases were
also observed in the AVR group. Previous valve replacement surgery was
observed in 19 patients (8.6%) in the AVR group, 108 patients (28.3%)
in the MVR group, and 29 patients (31.2%) in the DVR group (Table 1).diovascular Surgery c Volume 147, Number 5 1493
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CM ¼ CarboMedics
DVR ¼ double valve replacement
MVR ¼ mitral valve replacement
%/Pt-Yrs ¼ percentage per patient-years
Pt-Yrs ¼ patient-years
PVE ¼ prosthetic valve endocarditis
PVL ¼ paravalvular leakage
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DThe details regarding surgery and patient care have been previously
described.3,4 In brief, all patients underwent surgery using standard
cardiopulmonary bypass with moderate hypothermia (at 28-34C). Either
cold crystalloid5 or blood cardioplegia, associated with ice slush topical
cooling, was delivered, either antegrade or retrograde, or both. Everting
mattress sutures with 2-0 braided polyester sutures reinforced with polyte-
trafluoroethylene (Teflon) felt pledgets were the predominant method used
to suture the valves.6 Horizontal mattress sutures, the single suture tech-
nique, or the annular enlargement technique4 were applied for AVR of
the small aortic annulus. The modified Bentall operation with direct sutur-
ing of the coronary button to a tube graft with CM prosthesis was applied in
31 patients, and the Cabrol modification was applied in 2 patients. In the
AVR,MVR, and DVR groups, concomitant coronary artery bypass grafting
was performed in 17, 25, and 2 patients, respectively. In 6 patients with par-
avalvular leakage (PVL), glutaraldehyde-preserved pericardial xenografts
were used to repair and reinforced the mitral annulus responsible for the
PVL.
Heparin calcium of 5000 or 7500 U was administered subcutaneously
every 12 hours starting on the first postoperative day until the international
normalized ratio of the prothrombin time reached a therapeutic range with
oral warfarin administration. After discharge from our hospital, the interna-
tional normalized ratio of the prothrombin timewasmeasured at least every
4 weeks andmaintained at 2.0 to 2.8 in theMVR or DVR patients and 1.8 to
2.4 in the AVR patients.
Early postoperative and then monthly or annual follow-up was per-
formed for most patients by us in our outpatient clinic. We directly inter-
viewed the ‘‘visit-interrupted’’ patients themselves, their families, or
physicians using questionnaires sent by mail or telephone. If we were in-
formed of the patient’s death in the response to our questionnaire, we di-
rectly interviewed the physician in charge to reconfirm the cause of
death and/or any related complications.
Five patients could not be contacted; thus, the follow-up data were com-
plete for 99.3% of the patients. The mean follow-up period was 10.4 years
(12.0 0.4 years in the AVR group, 9.1 0.3 years in theMVR group, and
11.7 0.7 years in the DVR group), with 7201 patient-years (Pt-Yrs). The
cumulative follow-up included 2628 Pt-Yrs in the AVR group, 3482 Pt-Yrs
in the MVR group, and 1091 Pt-Yrs in the DVR group.
Hospital and late deaths and all valve-related mortalities and compli-
cations were strictly defined according to the published guidelines of the
American Association of Thoracic Surgery and the Society of Thoracic
Surgeons.7 All continuous variables are presented as the mean  stan-
dard error of the mean. Fisher’s exact test and Student’s t test were
used for the univariate analyses. The incidence of death and events is
expressed in linearized form (percentage per Pt-Yrs [%/Pt-Yrs]). The ac-
tuarial8 survival rates and freedom from valve-related morbidities were
calculated using the actuarial life table (Kaplan-Meier) method and
reported using the standard error of the mean. Comparisons of these es-
timates were made using the log-rank test. P<.05 was considered to be
significant.1494 The Journal of Thoracic and Cardiovascular SurRESULTS
Early Mortality (Primary Plus Redo Cases)
A total of 20 early deaths occurred within 30 days of
surgery and 18 in-hospital deaths that occurred within any
interval after surgery. The early mortality rate was 2.9%
(20 of 694) for all patients, 0.9% (2 of 220) in the AVR
group, 3.7% (14 of 381) in the MVR group, and 4.3%
(4 of 93) in the DVR group. The cause of early death was
predominantly low output syndrome (in 15 patients) due
to a prolonged cardiac ischemic time during surgery. No
valve-related death due to prosthetic valve endocarditis
(PVE), PVL, or other valve dysfunction was observed.
Renal failure (in 3 patients), colon perforation (in 1 patient),
and cerebral bleeding (in 1 patient) due to head traumawere
the other causes of early death.Late Mortality (Primary Plus Redo Cases)
Figure 1 shows the rates of freedom from valve-related
death and cardiac death and actuarial survival. The linear-
ized ratio of the AVR, MVR, and DVR groups was 1.0%,
1.1%, and 0.8%/Pt-Yrs for valve-related death, 1.3%,
1.8%, and 1.3%/Pt-Yrs for cardiac death, and 2.8%,
3.9%, and 3.3%/Pt-Yrs for all-cause death, respectively.
The predominant cause of late death was sudden or unex-
pected death (from unknown causes) for the valve-related
deaths, chronic heart failure for the non–valve-related car-
diac deaths, and cancer for the noncardiac deaths. Regard-
ing the other causes of late death, no significant
differences were observed in the incidence of thromboem-
bolism, bleeding events, thrombosed valves, or PVE among
the 3 groups.Valve-Related Morbidity (Primary Plus Redo Cases)
No structural valve deterioration was observed in the
AVR, MVR, and DVR groups. PVL, pannus formation,
bleeding events, thromboembolism, valve thrombosis,
PVE, and additional reoperations were associated with the
valve-related morbidity. The linearized ratios for each event
are listed in Table 2. The actuarial freedom from valve-
related morbidity was significantly higher in the AVR group
than in the MVR or DVR groups (P ¼ .0068; Table 2).
A total of 61 bleeding events were observed (Table 1), in-
cluding 38 cases of intracranial bleeding, 21 cases of gastro-
intestinal bleeding, 1 case of urinary tract bleeding, and 1
case of peripheral bleeding. The actuarial freedom from
bleeding events at 10 and 20 years after surgery was
93.5%  1.8% and 88.4%  3.6% in the AVR group,
91.5%  1.8% and 82.2%  4.0% in the MVR group,
and 93.2%  2.9% and 84.9%  5.5% in the DVR group,
respectively.
A total of 73 thromboembolism events were observed
(Table 2), including 60 cases of brain infarction, 8 cases
of peripheral events, and 5 cases of transient ischemicgery c May 2014
TABLE 1. Patient profiles and valve disease etiology
Variable
AVR
(n ¼ 220)
MVR
(n ¼ 381)
DVR
(n ¼ 93)
Male gender 160 169 50
Age (y) 54.9  0.94 60.0  0.56* 56.2  1.1
Valve disease etiology (n)
Rheumatic, degenerative,
congenital
152 (69.1) 228 (60.0) 58 (62.4)
Active IE 6 (2.8) 16 (4.2) 9 (6.7)
Healed IE 11 (5.0) 5 (1.3) 0
Active PVE 1 (0.5) 4 (1.1) 4 (4.3)
Healed PVE 0 3 (0.79) 4 (4.3)
Paravalvular leakage 1 (0.5) 27 (7.1) 2 (2.2)
SVD of previous bioprostheses 14 (6.4) 68 (17.9) 17 (18.3)
Annulo-aortic ectasia 25 (11) 0 0
Aortitis 2 (0.9) 0 0
Acute aortic dissection 5 (2.3) 0 0
Chronic aortic dissection 2 (0.9) 0 0
Pseudo-aneurysm formation 2 (0.9) 0 0
Valve thrombosis 0 2 (0.53) 1 (1.1)
Pannus formation 0 1 (0.26) 0
After mitral valve plasty 0 30 (7.9) 1 (1.1)
Acute mitral regurgitation 0 1 (0.26) 0
Previous any valve replacement 19 (8.6) 108 (28.3) 29 (31.2)
Data are presented as mean standard deviation or n (%). AVR, Aortic valve replace-
ment; MVR, mitral valve replacement; DVR, double valve replacement; IE, infective
endocarditis; PVE, prosthetic valve endocarditis; SVD, structural valve deterioration.
*P<.05 versus AVR.
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Dattack. The actuarial freedom from thromboembolism at 10
and 20 years after surgery was 89.9%  2.4% and 88.0%
 2.6% in the AVR group, 90.3%  1.8% and 76.9% 
4.5% in the MVR group, and 90.2%  3.5% and 80.7%
 5.8% in the DVR group, respectively.
No significant differences were observed in the freedom
from bleeding events, thromboembolism, valve thrombosis,
and PVE (Table 2); however, PVL (Figure 2, A) and the re-
sulting reoperations (Figure 2, B) were more common in the
MVR and DVR groups than in the AVR group (P ¼ .0019
for freedom from PVL, Figure 2, A; P<.0001 for freedom
from reoperation, Figure 2, B). Thus, the AVR group
included only 7 cases (3.2%) of PVL, the MVR group
included 34 cases (8.9%) of PVL, and the DVR group in-
cluded 11 cases (11.8%) of mitral PVL (P ¼ .0019 vs
MVR and DVR; Table 2 and Figure 2, A).FIGURE 1. Entire long-term patient survival, including both primary and
redo cases, among the aortic valve replacement (AVR), mitral valve replace-
ment (MVR), and double valve replacement (DVR) groups. Freedom from
A, valve-related death, B, cardiac death, and C, all-cause death are shown.Comparison of Early and Late Results Between
Primary and Redo Cases
We further analyzed and compared our results between
the primary and redo operations, because the redo opera-
tions performed in the MVR and DVR groups might have
been responsible for the development of mitral PVL.
The hospital mortality rate of the redo AVR, MVR, and
DVR groups was 0% (0 of 19), 3.7% (4 of 108), andThe Journal of Thoracic and Car10.3% (3 of 29), respectively, without any significant differ-
ences between the primary and redo valve replacementdiovascular Surgery c Volume 147, Number 5 1495
TABLE 2. Linearized ratio and actuarial freedom from valve-related morbidity
Variable AVR (n ¼ 220) MVR (n ¼ 381) DVR (n ¼ 93)
Valve-related morbidity (%) 57 (26) 127 (33) 38 (41)
%/Pt-Yrs 2.2 3.6 3.5
Freedom from valve-related morbidity (number at risk)
At 5 y 90.2  2.1 (169) 84.3  2.0 (241) 88.4  3.5 (73)
At 10 y 81.4  2.9 (118) 76.4  2.6 (155) 75.3  4.8 (53)
At 15 y 69.9  3.8 (69) 57.4  3.6 (67) 60.1  6.0 (32)
At 20 y 66.0  4.2 (15) 40.6  5.3 (15) 48.0  6.8 (9)
Paravalvular leakage (%) 7 (3.2) 35 (8.9)* 11 (11.8)*
%/Pt-Yrs 0.27 1.0 1.0
Pannus formation (%) 0 1 (0.26) 0
%/Pt-Yrs 0 0.029 0
Bleeding events (%) 17 (7.7) 36 (9.4) 8 (8.6)
%/Pt-Yrs 0.65 1.0 0.73
Thromboembolism (%) 21 (9.5) 40 (10) 12 (13)
%/Pt-Yrs 0.8 1.1 1.1
Valve thrombosis (%) 1 (0.5) 10 (2.6) 1 (1.1)
%/Pt-Yrs 0.04 0.29 0.09
Prosthetic valve endocarditis (%) 11 (5.0) 6 (1.6) 6 (6.5)
%/Pt-Yrs 0.42 0.17 0.55
Additional redo valve operation (%) 6 (2.7) 41 (11)* 13 (14)*
%/Pt-Yrs 0.23 1.2 1.2
Data are presented as mean standard deviation or n (%). Pt-Yrs, Patient-years; AVR, aortic valve replacement;MVR, mitral valve replacement;DVR, double valve replacement.
*P<.05 versus AVR.
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valve replacement at 10 and 20 years was 48.9%  12%
and 48.9%  12% in the AVR group, 66.6%  5.2% and
43.7%  6.5% in the MVR group, and 62.8%  9.4% and
38.2% 11% in theDVR group, respectively. No significant
differenceswere found in the freedom fromvalve-relatedmor-
tality at 20 years after surgery between the primary and redo
operations in the AVR group (83.9%  3.4% and 77.5% 
12%, respectively), MVR group (69.6%  7.1% and
82.7%  5.4%, respectively), or DVR group (87.6% 
5.5% and 78.6%  9.6%, respectively). In contrast, the
freedom from valve-related morbidity rates at 20 years after
surgery in the redo MVR (27.6%  7.6%) and DVR
(35.6%  11%) groups were significantly lower than those
observed in the primary MVR (52.1%  7.9%, P<.0001)
and DVR (59.8%  8.4%, P ¼ .0123) groups.
Regarding the valve-related morbidity of redo valve re-
placement, PVL was observed most (34 of the 108 redo
MVR patients [31.5%] and 8 of the 29 redo DVR patients
[27.6%]), indicating a significantly higher incidence than
those (0.4-4.7%) observed in the primary groups (Table
3). In addition, 34 of the 35 mitral PVL cases (97%) oc-
curred after redo MVR and 8 of the 11 mitral PVL cases
(73%) occurred after redo DVR; no cases of PVL were ob-
served after redo AVR. No significant differences, however,
were observed in the incidence of bleeding events, throm-
boembolism, or valve thrombosis between the primary
and redo operations among the 3 groups (Table 3).
Freedom from additional reoperations at 10 and 20
years was 100% and 100% for the redo AVR group,1496 The Journal of Thoracic and Cardiovascular Sur80.4% 4.6% and 43.7% 11% for the redoMVRgroup,
and 86.7%  6.7% and 44.7%  13% for the redo DVR
group, respectively. Additional reoperations were per-
formed, first because of PVL in 30 of the 33 redo MVR pa-
tients (91%) and 8 of the 9 redo DVR patients (89%), and,
second, because of PVE in 3 of the 33 redo MVR patients
(9.1%) and 1 of the 9 redo DVR patients (11%; Table 3).
DISCUSSION
In the present report, we have demonstrated satisfactory
early and late results after valve replacement using CM
valves for both primary and redo valve replacement, with
the prostheses used in either the aortic position alone or
the mitral position alone, or both. No significant differences
were observed in hospital mortality or freedom from valve-
related death and cardiac death between the primary and
redo operations among the AVR, MVR, and DVR groups.
In contrast, the incidence of valve-related morbidity was
significantly higher in both theMVR-alone andDVRgroups
than in the AVR group. From our additional analysis, the rel-
atively higher incidence of valve-related morbidity could be
primarily ascribed to the occurrence of PVL around the mi-
tral annulus after either redo MVR or redo DVR.
Our present results, including hospital mortality, are
comparable to those reported by others’ using various bi-
leaflet mechanical valves such as CM valves,9-14 St Jude
Medical valve,12,15-17 and ATS valves.18-20 Because of the
relatively younger age and relatively fewer concomitant
operations such as coronary artery bypass grafting in our
series, it might not be possible to simply compare thesegery c May 2014
FIGURE 2. The long-term results of paravalvular leakage (PVL) and re-
operation among the aortic valve replacement (AVR), mitral valve replace-
ment (MVR), and double valve replacement (DVR) groups. Significant
differences were observed in the freedom from A, PVL and B, reoperation
among the 3 groups.
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redo valve operations among the 3 groups, although
a history of previous cardiac surgery itself is a well-
known risk factor that increases patient mortality.16,21,22
The actuarial freedom from valve-related, cardiac, and
all-cause death after the implantation of CM valves we
have reported are comparable to those from other reports
of bileaflet mechanical valves.12,15-19,23 No significant
differences were observed in the actuarial freedom from
valve-related death between primary and redo valve re-
placement among the AVR, MVR, and DVR groups in
our series, although some reports have shown significant
differences between primary and redo operations.9,21
Regarding patient survival, our present results have shown
the performance of CM prostheses to be satisfactory, even
20 years after the primary and redo operations.The Journal of Thoracic and CarThe incidence of bleeding events in our series was similar
to that of other current era devices, including St JudeMedical
valves15,23 and ATS valves.18 The incidence of transient is-
chemic attacks was lower than that reported by others.15,17
Because we could not examine all the patients every month
or even every year after surgery, some nonfatal incidents,
including transient ischemic attacks, might have been
missed during the follow-up period. No structural valve de-
terioration and only 1 case of pannus formation (0.14% of
all patients) after MVR were observed during the 22-year
study period. The blood-contacting surface on the sewing
ring of the CM valve is coated with pyrolite carbon to reduce
thrombogenicity and tissue growth. This characteristicmight
prevent the pannus formation causing valve dysfunction.
Among the several valve-related morbidities, a signifi-
cantly higher incidence of mitral PVL was observed after
MVR alone and DVR than after AVR alone (Table 2 and
Figure 2, A; P ¼ .0019). It should be noted that 97%
(34 of 35) of the cases of PVL after MVR alone occurred
after redo valve replacement and 73% (8 of 11) of the cases
of mitral PVL after DVR also occurred after redo surgery.
Although the precise reasons for the higher incidence of mi-
tral PVL after both the redo MVR and DVR are not clear,
our implantation technique itself during redo valve replace-
ment in the mitral position might have been responsible for
the PVL, at least in some patients, because the PVL had de-
veloped within 1 year in 7 of 34 patients. We have con-
firmed, however, that no obvious PVL had been observed
in the operating room before finishing the operation on
the intraoperative transesophageal echocardiograms since
1992. In general, moreover, the leakage had developed at
8.2 years on average after redo valve replacement in the mi-
tral position, and 7 patients had multiply recurrent PVL (3
times) that was counted as 16 mitral PVL cases. Thus, either
a destructive mitral annulus developed after removal of the
previous prosthesis or patient predisposition or the charac-
teristics of the sewing ring of the CM prosthesis, with or
without minor operative technical errors that could not be
detected on the intraoperative echocardiograms, might
have been responsible for our present results. The pyrolite
carbon, which is coated on the inflow surface of the sewing
ring of the CM prosthesis to reduce tissue growth, might
prevent organization and sealing between the sewing ring
and the mitral annulus after redo MVR. Schaff et al24 re-
ported a significantly higher incidence of PVL in the pa-
tients implanted with the SJM Silzone prosthesis and
speculated that the altered surface of the polyester sewing
ring coated with silver had some biologic effect because
of the thinner pannus formation over the Silzone portion
in an animal study. In this context, PVE was not likely to
be the main cause of PVL in our present series (Table 3).
Regarding the limitations of the present study, our study
was retrospective, and the patient number of the redo group
was small for comparing the primary and redo operations.diovascular Surgery c Volume 147, Number 5 1497
TABLE 3. Hospital death, valve-related morbidity, and cause of reoperation for primary and redo mitral or double valve replacement
Variable
MVR (n ¼ 381) DVR (n ¼ 93)
Primary (n ¼ 273) Redo (n ¼ 108) Primary (n ¼ 64) Redo (n ¼ 29)
Hospital death (%) 14 (3.6) 4 (4.3)
Stratified by group 10 (3.7) 4 (3.7) 1 (1.6) 3 (10.3)
Valve-related morbidity (%) 63 (23.1) 64 (59.3)* 19 (29.7) 19 (65.5)*
%/Pt-Yrs 2.4 7.0 2.3 7.0
Paravalvular leakage (%) 1 (0.42) 34 (31.5)* 3 (4.7) 8 (27.6)*
%/Pt-Yrs 0.08 3.5 0.37 2.9
Reoperation (%) 8 (2.9) 33 (30.6)* 4 (6.25) 9 (31.0)*
%/Pt-Yrs 0.31 3.6 0.49 3.3
Cause of reoperation (%/reoperation)
PVL 1 (13) 30 (91) 3 (75) 8 (89)
PVE 0 (0) 3 (9.1) 1 (25) 1 (11)
Pannus formation 1 (13) 0 (0) 0 (0) 0 (0)
Valve thrombosis 5 (63) 0 (0) 0 (0) 0 (0)
Other 1 (13) 0 (0) 0 (0) 0 (0)
Data are presented as n (%). MVR, Mitral valve replacement; DVR, double valve replacement; Pt-Yrs, patient-years; PVE, prosthetic valve endocarditis; PVL, paravalvular
leakage. *P<.05 versus primary group.
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and redo DVR group, respectively, with 108 cases included
in the redo MVR group.
CONCLUSIONS
Our long-term experience has confirmed that the CM
mechanical prostheses are safe for use in both primary
and redo operations. However, extreme care should be taken
to prevent mitral PVL during redo MVR or DVR surgery.
We would like to thank Mr Brian Quinn for reviewing our
report.
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